Meprobamate (marketed under the brand names Miltown by Wallace Laboratories, Equanil by Wyeth, and Meprospan) is a carbamate derivative which is used as an anxiolytic drug. It was the best-selling minor tranquilizer for a time, but has largely been replaced by the benzodiazepines.
Indications
Meprobamate is licensed for the short-term relief of anxiety, although it is not known whether the purported anti-anxiety effects of meprobamate are separable from its sedative effects. Its effectiveness as a selective agent for the treatment of anxiety has not been proven in humans, and is not used as often as the benzodiazepines for this purpose.
Meprobamate is available in 200 mg and 400 mg tablets for oral administration. Meprobamate is also a component of the combination drug Equagesic (discontinued in the UK in 2002) acting as a muscle relaxant.
 
Overdose
Symptoms of meprobamate overdose include: drowsiness, sluggishness, unresponsiveness, or coma; loss of muscle control; severe impairment or cessation of breathing; or shock. Death has been reported with ingestion of as little as 12g of meprobamate and survival with as much as 40g. In an overdose, meprobamate tablets may form a gastric bezoar, requiring physical removal of the undissolved mass of tablets through an endoscope; therefore, administration of activated charcoal should be considered even after 4 or more hours or if levels are rising.
Health issues
Meprobamate is a Schedule IV drug under the Convention on Psychotropic Substances. With protracted use it can cause physical dependence and has a spectacular and life-threatening abstinence syndrome similar to that of barbiturates and alcohol.
 
Preparations： tablet: 0.2g
Powder-injection: 0.1g.
Adverse reactions： drowsiness, weakness, skin rash, blood pressure, occasionally hematopoietic dysfunction (eg, neutropenia), take in long time can form dependent.

Methods of taking oral: Each 0.2 ~ 0.4g, 3 times a day, or bedtime 0.2 ~ 0.4g.

   Intramuscular or intravenous injection: 0.2 ~ 0.4g / time